Global Diabetic Nephropathy Market Size study & Forecast, by Drug Class (Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers, Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors, Mineralocorticoid Receptor Antagonists, Others), By

Global Diabetic Nephropathy Market Size study & Forecast, by Drug Class (Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers, Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors, Mineralocorticoid Receptor Antagonists, Others), By by Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies) and Regional Analysis, 2023-2030

Global Diabetic Nephropathy Market is valued at approximately USD 2.59 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 4.3% over the forecast period 2023-2030. Diabetic Nephropathy is a kidney ailment resulting from prolonged exposure to elevated blood sugar levels, a common consequence of diabetes. It is characterized by the occurrence of proteinuria, where proteins, notably albumin, are detected in the urine. Diabetic individuals face an increased risk of developing this condition. The assessment of glomerular filtration rate serves as a crucial measure to gauge the extent of kidney impairment associated with diabetic nephropathy. The Diabetic Nephropathy market Market is expanding because of factors such as the rise in the prevalence of diabetes and the growing population with cardiovascular diseases. As a result, the demand of for Diabetic Nephropathy has progressively increased in the international market during the forecast period 2023-2030.

Diabetes is often a chronic condition that requires long-term management. The longer individuals live with diabetes, the higher the likelihood of developing complications, including diabetic nephropathy. This chronic nature contributes to a sustained demand for diagnosis, treatment, and management of kidney complications. According to the International Diabetes Federation, in 2021, 537 million adults were diagnosed with diabetes and projected to reach up to 643 million in number by 2030 and 783 million adults by the year 2045. Another important factor that drives the Diabetic Nephropathy market Market is the growing population with cardiovascular diseases. Obesity, hypertension, and dyslipidemia are important risk factors for both diabetes and cardiovascular disease. Since the number of people with cardiovascular diseases grows, the possibility of that more people to will be susceptible to these common risk factors, which can contribute to the development of diabetic nephropathy. According to the World Health Organization (WHO), it was estimated that cardiovascular diseases are recorded as the leading cause of death around the world, which takes an estimated 17.9 million lives annually. Additionally, heart attacks and strokes account for 85% of these cardiovascular disease deaths. Moreover, technological advancements associated with diabetic nephropathy and supportive government initiatives towards the treatment of diabetes is are anticipated to create a lucrative growth opportunity opportunities for the market over the forecast period. However, the high cost associated with diabetic nephropathy and lack of standardization in nephropathy is going to impede overall market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Diabetic Nephropathy Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rising government and pharmaceutical organization efforts to raise awareness of kidney disease in the region. Awareness programs can provide valuable information about the link between diabetes and kidney disease, encouraging individuals to seek information about their health conditions. Accessible information empowers people to make informed decisions about their health and take proactive steps to prevent complications. The region’s dominant performance is anticipated to propel the overall demand of for Diabetic Nephropathy. Furthermore, Asia Pacific is expected to grow fastest during over the forecast period, owing to factors such as increased healthcare spending in the region. Increased healthcare spending can improve access to necessary medical treatments, medications, and healthcare services for individuals with Diabetic Nephropathy. This includes access to dialysis or kidney transplantation for those in advanced stages of the disease.

Major market player included in this report are:
Janssen Pharmaceuticals, Inc
AstraZeneca plc
Aurobindo Pharma Limited
Teva Pharmaceutical Industries Ltd
Sanofi S.A.
Novartis AG
Sun Pharmaceutical Industries Ltd
Bayer AG
Par Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd

Recent Developments in the Market:
 In January 2024, Neuralace Medical, Inc., a pain management technology inventor has announced its innovative product, Axon Therapy (mPNS), which has been cleared by the FDA for the treatment of persistent Painful Diabetic Neuropathy (PDN). This approval is the first time the FDA has cleared a non-invasive, magnetic peripheral nerve stimulation (mPNS) treatment for Painful Diabetic Neuropathy.

Global Diabetic Nephropathy Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Drug Class, Distribution Channel, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Drug Class
Angiotensin Converting Enzyme (ACE) Inhibitors
Angiotensin Receptor Blockers
Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
Mineralocorticoid Receptor Antagonists
Others

By Distribution Channel
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.